We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

UPLD:NASDAQUpland Software, Inc. Analysis

Data as of 2026-08-02 - not real-time

$4.36

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Upland Software (UPLD) is trading at roughly $4.36, well below its 20‑day SMA of $4.82 and the 50‑day SMA of $5.90, indicating a bearish price trend that sits just above the identified support level of $4.02 and far beneath the $5.69 resistance zone. The RSI of 41 suggests the stock is not yet oversold, while a bullish MACD signal (positive histogram) hints at a potential short‑term reversal, reinforced by an increasing volume trend. Volatility is extreme at nearly 94% over the past 30 days and beta exceeds 2, underscoring heightened market sensitivity. Fundamentally, the company faces steep challenges: revenue fell 23.5% YoY, profit margin is negative, and the balance sheet shows a debt‑to‑equity ratio above 290% with a negative book value per share. Nonetheless, adjusted EBITDA margin expanded to 31% in the latest quarter, and forward EPS is projected at $5.77, suggesting improving operational efficiency. The DCF‑derived fair value of roughly $91 translates to an implied upside of over 180%, while the market caps the company at just $12.8 M, reflecting a massive valuation disconnect. Recent material news indicates the firm regained Nasdaq’s $1 minimum bid price compliance and appointed a seasoned CFO, both of which could stabilize governance and support the strategic priorities outlined by management. Overall, the stock presents a classic high‑risk, high‑potential scenario where technical signs of a bottom are aligning with nascent operational improvements and a dramatically undervalued valuation.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 6/10

Key Factors

  • Price near support with bullish MACD signal
  • Increasing volume indicating renewed buying interest
  • Recent Nasdaq compliance restore confidence

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • EBITDA margin expansion to 31% and positive forward EPS
  • New CFO expected to improve capital structure
  • DCF fair value suggests substantial upside

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • High leverage and negative ROE pose structural risk
  • Revenue decline and negative profit margin remain concerns
  • Market volatility and beta indicate continued price swings

Key Metrics & Analysis

Financial Health

Revenue Growth-23.50%
Profit Margin-7.07%
P/E Ratio0.8
ROE-17.31%
ROA3.05%
Debt/Equity294.50
P/B Ratio-0.2
Op. Cash Flow$23.1M
Free Cash Flow$36.5M
Industry P/E32.8

Technical Analysis

TrendBearish
RSI41.3
Support$4.02
Resistance$5.69
MA 20$4.82
MA 50$5.90
MA 200$10.91
MACDBullish
VolumeIncreasing
Fear & Greed Index92.88

Valuation

Fair Value$90.91
Target Price$12.50
Upside/Downside186.70%
GradeUndervalued
TypeGrowth

Risk Assessment

Beta2.31
Volatility93.72%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.